Daptomycin formulations containing a combination of sorbitol and mannitol
AssigneesBaxter International Inc., Baxter Healthcare S.A.
InventorsLindsay Wegiel, Reagan Miller
Life of this patent
Estimating the term…
Loading patent…
AssigneesBaxter International Inc., Baxter Healthcare S.A.
InventorsLindsay Wegiel, Reagan Miller
Estimating the term…
In an aspect, a method of manufacture of a pharmaceutically acceptable solid composition containing daptomycin includes drying an aqueous solution containing (i) water, (ii) the daptomycin, (iii) sorbitol in an amount of about 1.2 wt. % to about 9.0 wt. % of total volume of the aqueous composition and (iv) mannitol in an amount of about 0.6 wt. % to about 9.5 wt. % of total volume of the aqueous composition to form the solid composition. The drying can include an sublimation drying of about −25° C. to about 50° C. for a time period of about 15 hours to about 120 hours, most preferably about 15° C. for about 20 hours, optionally preceded and/or followed by one or more additional drying steps. Other aspects are the solid composition containing the daptomycin and also methods of treating a bacterial infection including administering a pharmaceutically acceptable product made by reconstituting the solid composition.
A method of making a pharmaceutically acceptable solid composition comprising daptomycin, the method comprising drying an aqueous solution comprising (a) water, (b) the daptomycin, (c) sorbitol in an amount of about 1.2 wt. % to about 9.0 wt. % of total volume of the aqueous solution and (d) mannitol in an amount of about 0.6 wt. % to about 9.5 wt. % of the total volume of the aqueous solution to form the solid composition with a moisture content of about 1.0 wt. % or less relative to total weight of the solid composition.
Dependencies are inferred from the claim text.